Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Rigel Publishes Data On REZLIDHIA In Post-Venetoclax Patients With Mutant IDH1 AML In Leukemia & Lymphoma

Author: Benzinga Newsdesk | April 04, 2024 08:11am

Olutasidenib induced durable composite complete remission in 43.8% of patients relapsed or refractory to prior venetoclax-based regimens
Safety was consistent with the overall profile of olutasidenib
Olutasidenib may offer a valuable treatment option for patients with mIDH1 previously treated with venetoclax

Posted In: RIGL